Sac-TMT and KL-A167 for HR+/HER2- Breast Cancer
Part of Cancer, Skin clinical trials.
This trial is testing a combination of two drugs, Sac-TMT and KL-A167, in people with a certain type of advanced breast cancer (HR+/HER2-) that is PD-L1 positive. It's for those whose cancer has gotten worse after treatment with a CDK4/6 inhibitor and hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have HR-positive, HER2-negative breast cancer that is advanced or has spread.
- Your cancer has gotten worse while on or within 12 months of finishing a CDK4/6 inhibitor plus hormone therapy.
- Your cancer tests positive for PD-L1 (a protein that helps cancer hide from the immune system).
- You have at least one tumor that can be measured on scans, and your overall health is good (able to do daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs—Sacituzumab Tirumotecan (Sac-TMT) and an immunotherapy called KL-A167—given before surgery to shrink triple-negative breast tumors. It aims to improve outcomes for people with early-stage, high-risk breast cancer who have not yet had any treatment.
This trial tests a combination of two drugs for people with a specific type of advanced lung cancer that has a change in the ALK gene. The goal is to see if this combination works better than current treatments and to use a blood test to guide therapy.
This trial tests a combination of two drugs (SKB264 and KL-A167) for women with advanced ovarian, endometrial, or cervical cancer that has a specific genetic feature (MSI-H or dMMR). It aims to see if this combo can shrink tumors or slow cancer growth.
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
This trial tests a new combination of two drugs (Sac-TMT and Toripalimab) as the first treatment for women with advanced triple-negative breast cancer that is PD-L1 positive. The goal is to see if this combination can shrink or control the cancer better than standard treatments.
This trial tests two new medicines (SKB264 and KL-A167) given before surgery for people with a specific high-risk type of early-stage breast cancer (ER-positive, HER2-negative). The goal is to see if this combination can shrink tumors and improve outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.